#Targetable

𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐰𝐢𝐭𝐡 𝐂𝐢𝐫𝐜𝐮𝐥𝐚𝐭𝐢𝐧𝐠 𝐓𝐮𝐦𝐨𝐫 𝐂𝐞𝐥𝐥𝐬 (𝐂𝐓𝐂𝐬) 𝐢𝐧 𝐂𝐨𝐥𝐨𝐫𝐞𝐜𝐭𝐚𝐥 𝐂𝐚𝐧𝐜𝐞𝐫 𝐌𝐞𝐭𝐚𝐬𝐭𝐚𝐬𝐢𝐬. Cancers of the digestive system are becoming a growing health concern worldwide. Colorectal cancer is one of the most common cancers and one of the leading causes of cancer-related deaths globally. Scientists have discovered that tiny cancer cells can break away from the main tumor and travel through the bloodstream. These are called circulating tumor cells (CTCs). CTCs play a key role in helping cancer spread to distant organs. CTCs in in colorectal cancer and other digestive system cancers, provide the molecular basis for tumor dynamics monitoring, precision diagnosis and treatment. The recent advances of Precision Oncology with CTCs in Colorectal Cancer Metastasis is explained in the following video link. https://youtube.com/shorts/fvFtaYBXFBY 𝘈𝘵 𝘐𝘺𝘭𝘰𝘯 𝘗𝘳𝘦𝘤𝘪𝘴𝘪𝘰𝘯 𝘖𝘯𝘤𝘰𝘭𝘰𝘨𝘺 (www.iylon.com), 𝘸𝘦 𝘩𝘢𝘳𝘯𝘦𝘴𝘴 𝘨𝘦𝘯𝘦𝘵𝘪𝘤 𝘪𝘯𝘴𝘪𝘨𝘩𝘵𝘴 𝘵𝘰 𝘱𝘳𝘰𝘷𝘪𝘥𝘦 𝘱𝘦𝘳𝘴𝘰𝘯𝘢𝘭𝘪𝘻𝘦𝘥, 𝘦𝘷𝘪𝘥𝘦𝘯𝘤𝘦-𝘣𝘢𝘴𝘦𝘥 𝘳𝘦𝘤𝘰𝘮𝘮𝘦𝘯𝘥𝘢𝘵𝘪𝘰𝘯𝘴, 𝘩𝘦𝘭𝘱𝘪𝘯𝘨 𝘨𝘶𝘪𝘥𝘦 𝘵𝘩𝘦 𝘳𝘪𝘨𝘩𝘵 𝘮𝘦𝘥𝘪𝘤𝘪𝘯𝘦, 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘳𝘪𝘨𝘩𝘵 𝘱𝘢𝘵𝘪𝘦𝘯𝘵, 𝘢𝘵 𝘵𝘩𝘦 𝘳𝘪𝘨𝘩𝘵 𝘥𝘰𝘴𝘦, 𝘢𝘵 𝘵𝘩𝘦 𝘳𝘪𝘨𝘩𝘵 𝘵𝘪𝘮𝘦, 𝘢𝘯𝘥 𝘢𝘪𝘮𝘦𝘥 𝘢𝘵 𝘵𝘩𝘦 𝘳𝘪𝘨𝘩𝘵 𝘵𝘢𝘳𝘨𝘦𝘵. @senduraimani @jtarantino73

Circulating tumor cells, or CTCs, are cancer cells that break off from the original tumor and enter the bloodstream. They’re thought of as the “seeds” that can travel and potentially form new tumors in other areas of the body. Not every cell that breaks away survives, but these are the cells involved in spread. Even if we surgically remove a tumor or shrink it with chemotherapy, those circulating cells may still be present in the blood. Removing a visible tumor does not always mean that all malignant cells have been eliminated. Some cancer cells may continue to circulate at levels too small to detect on imaging. CTCs give us a way to assess whether there is residual systemic activity at a cellular level. They can reflect ongoing tumor shedding, treatment response, or persistent biologic activity that may not yet be measurable structurally. This is why we cannot think of cancer as just a localized mass to remove. We have to think about the terrain—the metabolic, immune, and hormonal environment that determines whether those circulating cells can survive, implant, and proliferate. A tumor does not metastasize simply because cells travel; it metastasizes when the environment allows those cells to take root. At the Center, we use RGCC CTC testing as a way to monitor this. The test isolates and analyzes circulating tumor cells from a blood sample, allowing us to assess whether there is ongoing tumor activity at a cellular level, even when scans are stable. In some cases, it can also evaluate how those cells respond to therapies. It usually requires a rotation of multiple therapies, but the goal is to get CTCs down to 0-1. 😊 #cancer #cancerscreening

Colorectal cancer is the #1 cause of cancer-related death for people under age 50, but it’s not just a U.S. issue. It’s a global one.🌎 How do we actually know who’s at higher vs. lower risk? And more importantly…how do we figure that out sooner? That’s exactly what Andrea Dwyer, MPH, leader of @fightcrc Global Think Tank for Early Onset Colorectal Cancer and director of the University of Colorado cancer screening program @colorado.cancer, is working on. She’s brought researchers, physicians, patients, and advocates from around the globe to the same table to tackle this challenge. Here’s the thing that might surprise you: There are brilliant researchers and doctors doing innovative work everywhere, but not every country starts with the same funding, data systems, or research infrastructure.🩺 If we want real answers — about risk, prevention, and earlier detection — for our generation, we must have global collaboration.🌎 Sharing knowledge across borders means we can protect more lives from colorectal cancer, sooner. 🎧💜Listen to the full episode with Andrea and the Global Think Tank’s co-lead Kiran Ilagan, DrPH, at the link in bio or on the YMyHealth podcast feed on your favorite podcasting platform. #ymyhealthpodcast #fightcrc #colorectalcancer #cancerresearch

Let’s talk about circulating tumor DNA. If there are cancer cells in the body, as they die, a small amount of cancer cell DNA is released into blood circulation. We can sequence the primary tumor to identify the mutations present in the cancer, and then test for those mutations in the blood. Detection of circulating tumor DNA (ctDNA) in blood, after treatment for primary breast cancer, is associated with a higher risk of future recurrence. Signatera is one test available to look for ctDNA but there are many others (through companies like Caris and Guardant as well). ***we can’t always detect ctDNA especially in early stage cancer and there are limitations to the technology as well. There is some nuance with this test and we often don’t know what to do if the results come back positive but staging scans are negative. Fortunately, there are many ongoing exciting clinical trials with ctDNA in breast cancer looking at interventions so hopefully we will have more answers soon! Currently on clinical trials.gov, there are about 100 breast cancer ctDNA trials! I want to highlight three that I think are important (but there are others!): 1. Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests. (HEROES) 2. DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE) (DARE) 3. Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) Let me know your questions or thoughts on #ctDNA! #breastcancer

About 80 percent of colorectal cancer cases occur in adults over 55. Age remains the strongest risk factor. But roughly 20 percent of cases now occur in people under 55, and incidence in younger adults has been increasing over the past few decades. Both of those facts matter. That shift is one reason screening now begins at age 45 for average-risk adults in the United States. Most patients are older. Younger patients are not rare. That nuance is important.

March Mission: GGC DNA Fights Colon Cancer Heredity #CancerAwarenessGGC" Worldwide, March marks Colorectal Cancer Awareness—1.9M hit yearly, 90% savable early! Silent polyps to cancers; GGC's exome/genetic tests ID risks like Lynch. Screen routinely, fuel with veggies, stay active. Global win: Lisa's hereditary alert—family thriving! Precision genetics empowers. General Genetics Corporation (GGC DNA): Expert testing: ggcdna.com | | #ColorectalAwarenessMonth #GGCDNA #PurpleForPrevention #GeneticScreening #BeatCancer

Every 3 months this kit from my oncologist comes in the mail. It’s a blood test that shows if there is any circulating tumor DNA in my blood. It can detect a tumor months before a tumor would show up on a scan. Comment TEST to learn more. FAQ: 1. Who orders the lab? - My oncologist 2. How much is it? - My insurance pays 100% 3. Where do you go for this lab? - They come to my house 4. Is this for any kind of cancer? - I’m not sure. You’d have to ask your oncologist if it’s being used for your cancer type. 5. How accurate is it? - Some people report that it gave a false/positive. From my research and experience, it’s pretty accurate for colon cancer. Remember, when this test comes in the mail…your heart may sink. Your stomach might hurt, but don’t let seeds land in that soil. Surrender it. ❤️ Share this with someone so they know to ask for this lab too! @nateragenetics @colorectalcanceralliance #cancer #colorectalcancer #cancersurvivor #bloodtest cancertesting

Comment CONVERSATION for the seven questions to ask your care team for any cancer diagnosis. ——- A colorectal cancer diagnosis creates urgency. And urgency feels responsible. Cancer care moves quickly — for good reason. But in the first 30 days, decisions get made that can’t be undone. Surgery gets scheduled. Chemo is framed as “standard.” Radiation feels automatic. Before you commit, pause and ask: • Has MMR/MSI testing been completed — and does it change my treatment path? • Are KRAS, NRAS, and BRAF results back before we finalize systemic therapy? Is HER2 testing relevant for me? How do these tests change my treatment options? • If this is rectal cancer, what are the pros and cons of total neoadjuvant therapy (TNT) instead of immediate surgery? • In Stage II or III disease, is ctDNA actionable in my case — and if positive or negative, what would we do differently? • Based on my age and tumor features, should I have germline genetic testing? • What are the long-term trade-offs — neuropathy, bowel dysfunction, fertility, ostomy risk — and are there alternatives? Speed can save lives. But clarity protects quality of life. The first 30 days shape the next 30 years. Save this for the first appointment cycle. Share it with someone newly diagnosed. #ColorectalCancer #ColonCancer #RectalCancer #CancerDiagnosis #NewlyDiagnosed

Adenocarcinoma is the most common type of colon cancer, accounting for approx. 96% of all colorectal cancers. • There has been a noticeable increase in early-onset colorectal cancer (diagnosed before age 50) • Currently, 20% of colorectal cancers occur in patients younger than 54 (up from 11% in 1995) ❓Why do you think there’s been an increase in early-onset colorectal cancer? Source: Increasing Incidence of Early-Onset Colorectal Cancer. N Engl J Med. April 20, 2022. #coloncancer #health #cancer #pathology #underthemicroscope

🧬 If you or a loved one has just been diagnosed with liver cancer or bile duct cancer (cholangiocarcinoma) — there’s one question you must ask: 👉 “Should we do genetic testing?” Most people think genetic tests are only for breast or colon cancer. But in liver and bile duct cancers, genomic profiling can reveal targetable mutations — opening doors to precision therapies. ✅ When do we consider genetic testing? – In advanced hepatocellular carcinoma (HCC) → testing for mutations like MET, TP53 (especially after first-line treatments fail) – In bile duct cancers (cholangiocarcinomas) → where up to 40% carry mutations like IDH1, FGFR2, BRAF (which can be treated with oral targeted drugs) – In young patients or strong family history → germline testing may reveal inherited cancer syndromes 💡 Why it matters: Genetic testing helps us move away from “one-size-fits-all” chemo — and towards personalized, precision cancer care. 📌 If you or someone you know is facing liver or bile duct cancer — don’t forget to ask your oncologist: “Would genetic testing change our treatment plan?” That one question could unlock more — and better — options. #GeneticTesting #LiverCancer #BileDuctCancer #Cholangiocarcinoma #CancerAwareness PrecisionOncology TargetedTherapy OncologyCare CancerEducation CancerSupport HCC CancerTreatmentOptions PersonalizedMedicine OncologyAwareness ModernCancerCare [genetic testing liver cancer, genomic profiling bile duct cancer, cholangiocarcinoma genetic testing, liver cancer targetable mutations, bile duct cancer targeted therapy, hepatocellular carcinoma genetic testing, precision oncology liver cancer, IDH1 FGFR2 mutations cholangiocarcinoma, germline testing liver cancer, personalized cancer treatment, targeted therapy in liver and bile duct cancer]

7 Signs of Cancer—Genetic Test Ends the Fear Swollen lymph nodes, bowel changes, fatigue—cancer symptoms ignite global fears: stigma, doubts, pressures, confusion. Counter with genetic cancer testing—scientific truth without fear, 99.99% precise DNA ending doubt for ultimate peace of mind. Like paternity testing mends families, this resolves health conflicts, protects wellbeing via early risk ID (NGS panels), and brings psychological relief—healing through knowledge. Reassuring, child/family-focused empowerment. Symptoms are signals—respond wisely. General Genetics Corporation (GGC DNA): Global confidential genetic cancer solutions. Contact: ggcdna #CancerSymptoms #GeneticCancerTest #EarlyDetection #PeaceOfMind #GGCDNA #AccurateDNAResults #ConfidentialTesting

Colorectal cancer can be completely silent in its early stages. No pain, no obvious symptoms and nothing that feels “wrong.” 🫥 March is Colorectal Cancer Awareness month, and we want you to know why screening matters so much. Catching it early doesn’t just make treatment easier… it can mean a 100% chance of cure. If you’re over 40, this is your gentle reminder not to put it off. If you’ve been meaning to book your screening, let this be your sign. 👨‍⚕️ Professor Atif Alvi, Consultant Colorectal, Laparoscopic & General Surgeon For booking enquiries, contact our call centre 📞800 7777, WhatsApp us via the link in our bio 💬, or book directly via your King’s Hub App 📲 Have you booked your screening? ⬇️